Back to search

Article

Discovery and preclinical efficacy of HSG4112, a synthetic  structural analog of glabridin, for the treatment of obesity

2020-07-09

Abstract excerpt

<h4>Background: </h4> : HSG4112 is a clinical-stage drug candidate for the treatment of obesity. Here, we report its discovery and preclinical efficacy.   <h4>Methods: </h4> : In high-fat diet (HFD)-induced obese male C57BL/6J mice, we tested the weight loss effect of synthetic compounds derived from a structure-activity relationship (SAR) study of glabridin, a natural compound known to reduce body weight and inf...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2908a994-c97b-5f58-a17b-4aa70874c0d0
DOI
10.22541/au.158282438.81737534/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesityDOI 10.22541/au.158282438.81737534/v2
Select a neighboring publication to make it the new centre.